MOUNTAIN VIEW, Calif., Nov. 4, 2010 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at two investment conferences during the month of November.
The conference presentation schedule is as follows:
Credit Suisse 2010 Healthcare Conference |
|
November 12, 2010 at 9:30 a.m. MST |
|
Arizona Biltmore Hotel, Phoenix, AZ |
|
Lazard Capital Markets 7th Annual Healthcare Conference |
|
November 16, 2010 at 3:10 p.m. EST |
|
St. Regis Hotel, New York, NY |
|
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: |
|||
VIVUS, Inc. |
Investor Relations: |
The Trout Group |
|
Timothy E. Morris |
Brian Korb |
||
Chief Financial Officer |
|||
650-934-5200 |
646-378-2923 |
||
SOURCE VIVUS, Inc.
Share this article